- Report
- March 2025
- 189 Pages
Global
From €3360EUR$3,545USD£2,807GBP
€3733EUR$3,939USD£3,119GBP
- Report
- April 2024
- 137 Pages
Global
From €2843EUR$2,999USD£2,375GBP
- Report
- December 2024
- 133 Pages
Global
From €3744EUR$3,950USD£3,128GBP
- Report
- April 2025
- 183 Pages
Global
From €4692EUR$4,950USD£3,920GBP
- Clinical Trials
- November 2024
- 240 Pages
Global
From €2843EUR$3,000USD£2,376GBP
- Report
- June 2024
- 200 Pages
Global
From €7535EUR$7,950USD£6,295GBP
- Clinical Trials
- June 2024
- 240 Pages
Global
From €2843EUR$3,000USD£2,376GBP
- Clinical Trials
- June 2024
- 447 Pages
Global
From €3270EUR$3,450USD£2,732GBP
- Report
- May 2024
- 128 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- May 2024
- 200 Pages
Global
From €3933EUR$4,150USD£3,286GBP
- Report
- December 2024
- 182 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- September 2023
- 180 Pages
Global
From €4407EUR$4,650USD£3,682GBP
- Report
- November 2022
- 63 Pages
Global
From €4692EUR$4,950USD£3,920GBP
- Report
- August 2022
- 118 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Drug Pipelines
- September 2022
- 30 Pages
Global
From €2606EUR$2,750USD£2,178GBP
- Report
- August 2022
- 30 Pages
Global
From €3080EUR$3,250USD£2,573GBP
- Report
- August 2022
- 30 Pages
Global
From €3080EUR$3,250USD£2,573GBP
- Report
- January 2022
- 200 Pages
Global
From €7109EUR$7,500USD£5,939GBP
- Report
- January 2022
- 60 Pages
Global
From €3744EUR$3,950USD£3,128GBP
- Report
- March 2024
- 267 Pages
Global
From €7535EUR$7,950USD£6,295GBP

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that affects the motor neurons in the brain and spinal cord. As a result, patients experience muscle weakness, paralysis, and eventually death. The ALS drug market is a subset of the Central Nervous System (CNS) drug market, which includes drugs used to treat neurological disorders such as Alzheimer’s, Parkinson’s, and Multiple Sclerosis. The ALS drug market is relatively small compared to other CNS drug markets, but it is growing due to increased awareness and research into the disease.
The ALS drug market is composed of both generic and branded drugs. Generic drugs are typically used to treat the symptoms of ALS, while branded drugs are used to slow the progression of the disease. Currently, there are several companies that are actively researching and developing new treatments for ALS, including Biogen, Novartis, and Sanofi. Additionally, there are several companies that are focused on providing generic drugs to treat the symptoms of ALS, such as Mylan and Teva Pharmaceuticals. Show Less Read more